Disease landscape

Follicular Lymphoma clinical trials

Get alerts when Follicular Lymphoma trials change

260 active trials 136 recruiting 30 Phase 3 147 sponsors 45 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days showing 39 of 45 changes on 20 trials

2026-08-15
Primary completion pushed: 2029-01-23 → 2031-04-30
Primary endpoint(s) modified
Enrollment increased: 470 → 580 participants
Completion pushed: 2029-01-23 → 2031-04-30
NCT06149286 A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better… · Regeneron Pharmaceuticals · Phase 3
2026-08-28
Primary completion pushed: 2026-08-12 → 2027-08-12
Completion pushed: 2027-02-12 → 2028-02-12
NCT06442475 Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma · University of Washington · Phase 2
2026-08-27
Primary completion pushed: 2026-08-11 → 2027-08-10
Completion pushed: 2026-08-11 → 2027-08-10
NCT06112847 Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma · City of Hope Medical Center · Phase 2
2026-08-14
Primary completion pushed: 2027-11-24 → 2028-04-21
NCT06526793 Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R)… · AstraZeneca · Phase 2
2026-08-28
Primary completion pushed: 2026-07 → 2027-07
Completion pushed: 2026-07 → 2027-07
NCT04464200 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · Memorial Sloan Kettering Cancer Center · Phase 1
2026-07-30
Primary completion pushed: 2026-09 → 2027-09
Primary endpoint(s) modified
NCT05365659 IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas · Iksuda Therapeutics Ltd. · Phase 1
2026-08-21
Primary completion pushed: 2026-08-01 → 2027-08-01
Completion pushed: 2027-08-01 → 2028-08-01
NCT04007029 Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or… · Jonsson Comprehensive Cancer Center · Phase 1
2026-08-11
Primary completion pushed: 2026-12 → 2027-12
Completion pushed: 2026-12 → 2027-12
NCT05389293 A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma · Memorial Sloan Kettering Cancer Center · Phase 2
2026-07-31
Primary completion pushed: 2030-01-15 → 2030-04-30
Recruitment opened
Trial sites expanded: 1 → 34 locations
Completion pushed: 2030-01-15 → 2030-04-30
NCT07197307 Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large… · Universität Münster · Phase 2
2026-08-22
Primary endpoint(s) modified
NCT05006716 A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With… · BeOne Medicines · Phase 1/2
2026-08-13
Primary completion pushed: 2026-07 → 2027-07
Completion pushed: 2026-07 → 2027-07
NCT04468841 Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma · Memorial Sloan Kettering Cancer Center · Phase 1
2026-08-07
Primary completion pushed: 2026-07 → 2028-07
Completion pushed: 2027-07 → 2030-07
NCT05990465 LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell… · Medical College of Wisconsin · Phase 1
2026-08-11
Primary endpoint(s) modified
NCT04224493 A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of… · Epizyme, Inc. · Phase 3
2026-08-12
Primary endpoint(s) modified
Recruitment opened
Enrollment increased: 30 → 40 participants
Trial sites expanded: 0 → 4 locations
Completion pushed: 2029-03-01 → 2030-03-01
NCT07191249 Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously… · Tel-Aviv Sourasky Medical Center · Phase 2
2026-08-14
Recruitment opened
NCT07562022 A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in… · Sinocelltech Ltd. · Phase 3
2026-08-05
Enrollment closed, study ongoing
NCT06191744 Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral… · Genmab · Phase 3
2026-07-31
Recruitment opened
NCT07609862 A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies · Guangzhou Lupeng Pharmaceutical Company LTD. · Phase 1/2
2026-07-31
Recruitment opened
Trial sites expanded: 2 → 6 locations
NCT07424833 A Study of APG-3288 in Relapsed/Refractory Blood Cancers · Ascentage Pharma Group Inc. · Phase 1
2026-08-20
Trial sites expanded: 224 → 228 locations
NCT06549595 A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular… · AstraZeneca · Phase 3
2026-08-08
Trial sites expanded: 13 → 16 locations
NCT07634471 A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) · Merck Sharp & Dohme LLC · Phase 2/3

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-26 NCT07788118 A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell… Second Affiliated Hospital, Zhejiang University, School of Medicine new Phase 1/2
2026-08-06 NCT07750886 Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin… Natera, Inc. new
2026-07-30 NCT07735533 A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies Umoja Biopharma new Phase 1/2
2026-07-30 NCT07736950 A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without… Australasian Leukaemia and Lymphoma Group new Phase 3
2026-07-22 NCT07719855 A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of… Ruijin Hospital new Phase 3

Active trials by phase

Early Phase 1
3
Phase 1
61
Phase 1/2
39
Phase 2
84
Phase 2/3
3
Phase 3
27
Not charted: 43 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 260

NCT IDTitleSponsorStatusUpdated
Phase 3
NCT06337318 Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden… National Cancer Institute (NCI) Recruiting 2026-08-27
NCT06549595 A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular… AstraZeneca Recruiting 2026-08-19
NCT06149286 A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better… Regeneron Pharmaceuticals Recruiting 2026-08-14
NCT07562022 A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in… Sinocelltech Ltd. Recruiting 2026-08-13
NCT06091254 A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works… Regeneron Pharmaceuticals Recruiting 2026-08-10
NCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib) Janssen Research & Development, LLC Recruiting 2026-07-31
NCT06284122 Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy… The Lymphoma Academic Research Organisation Recruiting 2026-06-05
NCT05929222 Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage… Fondazione Italiana Linfomi - ETS Recruiting 2026-06-01
NCT06911502 A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab… Celgene Recruiting 2026-05-20
NCT05045664 Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody Heidelberg University Recruiting 2026-04-28
NCT07029217 A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas Memorial Sloan Kettering Cancer Center Recruiting 2026-02-17
NCT04834024 MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab… Beijing Mabworks Biotech Co., Ltd. Recruiting 2024-11-20
NCT05100862 A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants… BeOne Medicines Active, Not Recruiting 2026-08-19
NCT04224493 A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of… Epizyme, Inc. Active, Not Recruiting 2026-08-10
NCT07736950 A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without… Australasian Leukaemia and Lymphoma Group Not Yet Recruiting 2026-08-06
NCT06191744 Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral… Genmab Active, Not Recruiting 2026-08-04
NCT07719855 A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of… Ruijin Hospital Not Yet Recruiting 2026-07-22
NCT04712097 A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With… Hoffmann-La Roche Active, Not Recruiting 2026-07-10
NCT05409066 Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral… Genmab Active, Not Recruiting 2026-07-08
NCT05058404 Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment… Fondazione Italiana Linfomi - ETS Active, Not Recruiting 2026-06-26
NCT05888493 A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult… Novartis Pharmaceuticals Active, Not Recruiting 2026-04-17
NCT06097364 A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated… Regeneron Pharmaceuticals Active, Not Recruiting 2026-02-06
NCT07355283 IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in… ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Not Yet Recruiting 2026-01-27
NCT04680052 A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and… Incyte Corporation Active, Not Recruiting 2025-12-22
NCT05371093 Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With… Kite, A Gilead Company Active, Not Recruiting 2025-10-15
See all 260 active Follicular Lymphoma trials with filters →

Top sponsors by active trials in this area

City of Hope Medical Center (13) · National Cancer Institute (NCI) (11) · M.D. Anderson Cancer Center (9) · University of Washington (7) · Fondazione Italiana Linfomi - ETS (6) · Genmab (5) · Mayo Clinic (5) · Sun Yat-sen University (5) · Fred Hutchinson Cancer Center (4) · Institute of Hematology & Blood Diseases Hospital, China (4)

Get alerts when Follicular Lymphoma trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free